{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:20:54Z","timestamp":1784636454152,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12010-025-05255-8","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T02:39:19Z","timestamp":1747449559000},"page":"4999-5016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1"],"prefix":"10.1007","volume":"197","author":[{"given":"YanBin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanDong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoJuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenKun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueJiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4274-8036","authenticated-orcid":false,"given":"KuiXing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"5255_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3727\/096504020X15844389264424","volume":"28","author":"Y Qin","year":"2020","unstructured":"Qin, Y., Wang, Y., & Liu, D. (2020). miR-4792 inhibits acute myeloid leukemia cell proliferation and invasion and promotes cell apoptosis by targeting kindlin-3. Oncology Research, 28, 357\u2013369.","journal-title":"Oncology Research"},{"key":"5255_CR2","doi-asserted-by":"publisher","first-page":"103164","DOI":"10.1016\/j.critrevonc.2020.103164","volume":"157","author":"S Taghiloo","year":"2021","unstructured":"Taghiloo, S., & Asgarian-Omran, H. (2021). Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. Critical Reviews in Oncology Hematology, 157, 103164.","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"5255_CR3","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1080\/21691401.2019.1596930","volume":"47","author":"H Wang","year":"2019","unstructured":"Wang, H., He, H., & Yang, C. (2019). miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p. Artificial Cells, Nanomedicine, and Biotechnology, 47, 3671\u20133676.","journal-title":"Artificial Cells, Nanomedicine, and Biotechnology"},{"key":"5255_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jcm5030033","volume":"5","author":"JN Saultz","year":"2016","unstructured":"Saultz, J. N., & Garzon, R. (2016). Acute myeloid leukemia: A concise review. Journal of Clinical Medicine, 5, 33.","journal-title":"Journal of Clinical Medicine"},{"key":"5255_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/aps.2016.121","volume":"38","author":"L Deng","year":"2017","unstructured":"Deng, L., Jiang, L., Lin, X. H., Tseng, K. F., Liu, Y., Zhang, X., Dong, R. H., Lu, Z. G., & Wang, X. J. (2017). The PI3K\/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacologica Sinica, 38, 382\u2013391.","journal-title":"Acta Pharmacologica Sinica"},{"key":"5255_CR6","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell, L. F., & Cook, R. J. (2021). Advances in acute myeloid leukemia. Bmj, 375, n2026.","journal-title":"Bmj"},{"key":"5255_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-1426-1-13","volume":"1","author":"RM Teague","year":"2013","unstructured":"Teague, R. M., & Kline, J. (2013). Immune evasion in acute myeloid leukemia: Current concepts and future directions. Journal for Immunotherapy of Cancer, 1, 1.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"5255_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-021-01446-z","volume":"20","author":"V Singh","year":"2021","unstructured":"Singh, V., Uddin, M. H., Zonder, J. A., Azmi, A. S., & Balasubramanian, S. K. (2021). Circular RNAs in acute myeloid leukemia. Molecular Cancer, 20, 149.","journal-title":"Molecular Cancer"},{"key":"5255_CR9","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1126\/science.1149460","volume":"318","author":"S Vasudevan","year":"2007","unstructured":"Vasudevan, S., Tong, Y., & Steitz, J. A. (2007). Switching from repression to activation: MicroRNAs can up-regulate translation. Science, 318, 1931\u20131934.","journal-title":"Science"},{"key":"5255_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.critrevonc.2009.05.001","volume":"74","author":"H Zhao","year":"2010","unstructured":"Zhao, H., Wang, D., Du, W., Gu, D., & Yang, R. (2010). MicroRNA and leukemia: Tiny molecule, great function. Critical Reviews in Oncology Hematology, 74, 149\u2013155.","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"5255_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7150\/jca.13460","volume":"7","author":"YC Lu","year":"2016","unstructured":"Lu, Y. C., Chang, J. T., Chan, E. C., Chao, Y. K., Yeh, T. S., Chen, J. S., & Cheng, A. J. (2016). miR-196, an emerging cancer biomarker for digestive tract cancers. Journal of Cancer, 7, 650\u2013655.","journal-title":"Journal of Cancer"},{"key":"5255_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.critrevonc.2016.05.014","volume":"104","author":"M Weiss","year":"2016","unstructured":"Weiss, M., Brandenburg, L. O., Burchardt, M., & Stope, M. B. (2016). MicroRNA-1 properties in cancer regulatory networks and tumor biology. Critical Reviews in Oncology Hematology, 104, 71\u201377.","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"5255_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/jid.2014.479","volume":"135","author":"E Penna","year":"2015","unstructured":"Penna, E., Orso, F., & Taverna, D. (2015). miR-214 as a key hub that controls cancer networks: Small player, multiple functions. The Journal of Investigative Dermatology, 135, 960\u2013969.","journal-title":"The Journal of Investigative Dermatology"},{"key":"5255_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews Genetics, 12, 861\u2013874.","journal-title":"Nature Reviews Genetics"},{"key":"5255_CR15","first-page":"3384","volume":"11","author":"B Zhu","year":"2019","unstructured":"Zhu, B., Xi, X., Liu, Q., Cheng, Y., & Yang, H. (2019). MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4. Am J Transl Res, 11, 3384\u20133397.","journal-title":"Am J Transl Res"},{"key":"5255_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/leu.2014.231","volume":"29","author":"D Gerloff","year":"2015","unstructured":"Gerloff, D., Grundler, R., Wurm, A. A., Br\u00e4uer-Hartmann, D., Katzerke, C., Hartmann, J. U., Madan, V., M\u00fcller-Tidow, C., Duyster, J., Tenen, D. G., Niederwieser, D., & Behre, G. (2015). NF-\u03baB\/STAT5\/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 29, 535\u2013547.","journal-title":"Leukemia"},{"key":"5255_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tox.2012.05.012","volume":"299","author":"G Wang","year":"2012","unstructured":"Wang, G., Zhang, J., Dewilde, A. H., Pal, A. K., Bello, D., Therrien, J. M., Braunhut, S. J., & Marx, K. A. (2012). Understanding and correcting for carbon nanotube interferences with a commercial LDH cytotoxicity assay. Toxicology, 299, 99\u2013111.","journal-title":"Toxicology"},{"key":"5255_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.bbrc.2005.07.030","volume":"334","author":"SA Ciafr\u00e8","year":"2005","unstructured":"Ciafr\u00e8, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C. G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 334, 1351\u20131358.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"5255_CR19","doi-asserted-by":"publisher","first-page":"e0116321","DOI":"10.1371\/journal.pone.0116321","volume":"10","author":"B Hauser","year":"2015","unstructured":"Hauser, B., Zhao, Y., Pang, X., Ling, Z., Myers, E., Wang, P., Califano, J., & Gu, X. (2015). Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS ONE, 10, e0116321.","journal-title":"PLoS ONE"},{"key":"5255_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/abbs\/gmx132","volume":"50","author":"L Zhao","year":"2018","unstructured":"Zhao, L., Li, R., Xu, S., Li, Y., Zhao, P., Dong, W., Liu, Z., Zhao, Q., & Tan, B. (2018). Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer. Acta Biochimica et Biophysica Sinica (Shanghai), 50, 171\u2013180.","journal-title":"Acta Biochimica et Biophysica Sinica (Shanghai)"},{"issue":"1","key":"5255_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-019-0800-z","volume":"12","author":"W Huang","year":"2019","unstructured":"Huang, W., Fang, K., Chen, T. Q., Zeng, Z. C., Sun, Y. M., Han, C., Sun, L. Y., Chen, Z. H., Yang, Q. Q., Pan, Q., Luo, X. Q., Wang, W. T., & Chen, Y. Q. (2019). circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression. Journal of Hematology & Oncology, 12(1), 103.","journal-title":"Journal of Hematology & Oncology"},{"key":"5255_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.celrep.2019.04.081","volume":"27","author":"H Wang","year":"2019","unstructured":"Wang, H., Xiao, Z., Zheng, J., Wu, J., Hu, X. L., Yang, X., & Shen, Q. (2019). ZEB1 Represses neural differentiation and cooperates with CTBP2 to dynamically regulate cell migration during neocortex development. Cell Reports, 27, 2335-2353.e2336.","journal-title":"Cell Reports"},{"key":"5255_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/0008-5472.CAN-17-2476","volume":"78","author":"J Caramel","year":"2018","unstructured":"Caramel, J., Ligier, M., & Puisieux, A. (2018). Pleiotropic roles for ZEB1 in cancer. Cancer Research, 78, 30\u201335.","journal-title":"Cancer Research"},{"key":"5255_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871\u2013890.","journal-title":"Cell"},{"key":"5255_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ncb1722","volume":"10","author":"PA Gregory","year":"2008","unstructured":"Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10, 593\u2013601.","journal-title":"Nature Cell Biology"},{"key":"5255_CR26","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., zur Hausen, A., Brunton, V. G., Morton, J., Sansom, O., Sch\u00fcler, J., Stemmler, M. P., Herzberger, C., Hopt, U., Keck, T., Brabletz, S., & Brabletz, T. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology, 11, 1487\u20131495.","journal-title":"Nature Cell Biology"},{"key":"5255_CR27","first-page":"8711","volume":"13","author":"S Wang","year":"2021","unstructured":"Wang, S., Cheng, Z., Chen, X., Lu, G., Zhu, X., & Xu, G. (2021). CircUBXN7 mitigates H\/R-induced cell apoptosis and inflammatory response through the miR-622-MCL1 axis. American Journal of Translational Research, 13, 8711\u20138727.","journal-title":"American Journal of Translational Research"},{"key":"5255_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/biom10071040","volume":"10","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh, M., Ang, H. L., Moghadam, E. R., Mohammadi, S., Zarrin, V., Hushmandi, K., Samarghandian, S., Zarrabi, A., Najafi, M., Mohammadinejad, R., & Kumar, A. P. (2020). MicroRNAs and their influence on the ZEB family: Mechanistic aspects and therapeutic applications in cancer therapy. Biomolecules, 10, 1040.","journal-title":"Biomolecules"},{"key":"5255_CR29","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y. H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., Diao, L., Wang, J., Roybal, J., Patel, M., Ungewiss, C., Peng, D., Antonia, S., Mediavilla-Varela, M., Robertson, G., \u2026 Qin, F. X. (2014). Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 5, 5241.","journal-title":"Nature Communications"},{"key":"5255_CR30","doi-asserted-by":"publisher","first-page":"e1263412","DOI":"10.1080\/2162402X.2016.1263412","volume":"6","author":"MZ Noman","year":"2017","unstructured":"Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017). The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology, 6, e1263412.","journal-title":"Oncoimmunology"},{"key":"5255_CR31","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/hmg\/ddac155","volume":"31","author":"Q Tian","year":"2022","unstructured":"Tian, Q., Wu, T., Zhang, X., Xu, K., Yin, X., Wang, X., Shi, S., Wang, P., Gao, L., Xu, S., & Liu, X. (2022). Immunomodulatory functions of the circ_001678\/miRNA-326\/ZEB1 axis in non-small cell lung cancer via the regulation of PD-1\/PD-L1 pathway. Human Molecular Genetics, 31, 4094\u20134106.","journal-title":"Human Molecular Genetics"},{"key":"5255_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/intimm\/dxw014","volume":"28","author":"S Spranger","year":"2016","unstructured":"Spranger, S. (2016). Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. International Immunology, 28, 383\u2013391.","journal-title":"International Immunology"},{"key":"5255_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis, R. J., Van Waes, C., & Allen, C. T. (2016). Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncology, 58, 59\u201370.","journal-title":"Oral Oncology"},{"issue":"20","key":"5255_CR34","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391\u20132405.","journal-title":"Blood"},{"issue":"4","key":"5255_CR35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., & Sultan, C. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103(4), 620\u20135.","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"5255_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., B\u00fcchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., Levine, R. L., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G. J., Sanz, M., Sierra, J., Tallman, M. S., Tien, H. F., \u2026 Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424\u2013447.","journal-title":"Blood"},{"key":"5255_CR37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cbin.11136","volume":"43","author":"S Zheng","year":"2019","unstructured":"Zheng, S., Liu, Q., Ma, R., Tan, D., Shen, T., Zhang, X., & Lu, X. (2019). Let-7b-5p inhibits proliferation and motility in squamous cell carcinoma cells through negative modulation of KIAA1377. Cell Biology International, 43, 634\u2013641.","journal-title":"Cell Biology International"},{"key":"5255_CR38","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.tranon.2022.101432","volume":"22","author":"XY Chen","year":"2022","unstructured":"Chen, X. Y., Qin, X. H., Xie, X. L., Liao, C. X., Liu, D. T., & Li, G. W. (2022). Overexpression miR-520a-3p inhibits acute myeloid leukemia progression via targeting MUC1. Translational Oncology, 22, 101432.","journal-title":"Translational Oncology"},{"key":"5255_CR39","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","volume":"59","author":"C Berthon","year":"2010","unstructured":"Berthon, C., Driss, V., Liu, J., Kuranda, K., Leleu, X., Jouy, N., Hetuin, D., & Quesnel, B. (2010). In acute myeloid leukemia, B7\u2013H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunology, Immunotherapy, 59, 1839\u20131849.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"5255_CR40","doi-asserted-by":"publisher","first-page":"4024887","DOI":"10.1155\/2023\/4024887","volume":"2023","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y., Tan, S., Wang, H., Zhu, J., Li, J., Zhang, P., Wang, M., & Zhang, F. (2023). Mesenchymal stem cell-derived exosomal miRNA-222-3p increases Th1\/Th2 ratio and promotes apoptosis of acute myeloid leukemia cells. Analytical Cellular Pathology (Amsterdam), 2023, 4024887.","journal-title":"Analytical Cellular Pathology (Amsterdam)"},{"key":"5255_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2022.07.298","volume":"112\u2013113","author":"J Cao","year":"2022","unstructured":"Cao, J., Huang, S., & Li, X. (2022). Rapamycin inhibits the progression of human acute myeloid leukemia by regulating the circ_0094100\/miR-217\/ATP1B1 axis. Experimental Hematology, 112\u2013113, 60-69.e62.","journal-title":"Experimental Hematology"},{"key":"5255_CR42","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1080\/21655979.2022.2059609","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Chen, X., Liu, J., Jin, Y., & Wang, W. (2022). Circular RNA circ_0004277 inhibits acute myeloid leukemia progression through MicroRNA-134-5p \/ single stranded DNA binding protein 2. Bioengineered, 13, 9662\u20139673.","journal-title":"Bioengineered"},{"key":"5255_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/15384047.2020.1740054","volume":"21","author":"H Li","year":"2020","unstructured":"Li, H., Tian, X., Wang, P., Hu, J., Qin, R., Xu, R., Liu, K., Hao, J., & Tian, N. (2020). LINC01128 resisted acute myeloid leukemia through regulating miR-4260\/NR3C2. Cancer Biology & Therapy, 21, 615\u2013622.","journal-title":"Cancer Biology & Therapy"},{"key":"5255_CR44","doi-asserted-by":"publisher","first-page":"1275141","DOI":"10.1155\/2022\/1275141","volume":"2022","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Guo, X., Wang, L., Xing, L., Zhang, X., & Ren, J. (2022). miR-342-3p inhibits acute myeloid leukemia progression by targeting SOX12. Oxidative Medicine and Cellular Longevity, 2022, 1275141.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"5255_CR45","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D., & Li, L. (2020). PD-1\/PD-L1 pathway: Current researches in cancer. American Journal of Cancer Research, 10, 727\u2013742.","journal-title":"American Journal of Cancer Research"},{"key":"5255_CR46","doi-asserted-by":"publisher","first-page":"109652","DOI":"10.1016\/j.cbi.2021.109652","volume":"349","author":"Y Xia","year":"2021","unstructured":"Xia, Y., Wang, W. C., Shen, W. H., Xu, K., Hu, Y. Y., Han, G. H., & Liu, Y. B. (2021). Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1\/miR-454-3p\/ZEB1 axis-mediated VEGFA expression and PD-1\/PD-L1 checkpoint in NSCLC. Chemico-Biological Interactions, 349, 109652.","journal-title":"Chemico-Biological Interactions"},{"issue":"4","key":"5255_CR47","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago, L., & Gojo, I. (2020). Immune escape and immunotherapy of acute myeloid leukemia. The Journal of Clinical Investigation, 130(4), 1552\u20131564.","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"5255_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018). Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Molecular Cancer, 17(1), 129.","journal-title":"Molecular Cancer"},{"issue":"593","key":"5255_CR49","doi-asserted-by":"publisher","first-page":"216969","DOI":"10.1016\/j.canlet.2024.216969","volume":"1","author":"M Xu","year":"2024","unstructured":"Xu, M., & Li, S. (2024). The opportunities and challenges of using PD-1\/PD-L1 inhibitors for leukemia treatment. Cancer Letters, 1(593), 216969.","journal-title":"Cancer Letters"},{"key":"5255_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/PPO.0000000000000297","volume":"24","author":"MJ Pianko","year":"2018","unstructured":"Pianko, M. J., Goldberg, A. D., & Lesokhin, A. M. (2018). Clinical development of PD-1 blockade in hematologic malignancies. Cancer Journal, 24, 31\u201335.","journal-title":"Cancer Journal"},{"key":"5255_CR51","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1016\/j.yexcr.2013.07.031","volume":"319","author":"M Li","year":"2013","unstructured":"Li, M., Fu, W., Wo, L., Shu, X., Liu, F., & Li, C. (2013). miR-128 and its target genes in tumorigenesis and metastasis. Experimental Cell Research, 319, 3059\u20133064.","journal-title":"Experimental Cell Research"},{"key":"5255_CR52","doi-asserted-by":"publisher","first-page":"105873","DOI":"10.1016\/j.biocel.2020.105873","volume":"131","author":"J Wang","year":"2021","unstructured":"Wang, J., Hu, X., Hu, X., Gao, F., Li, M., Cui, Y., Wei, X., Qin, Y., Zhang, C., Zhao, Y., & Gao, Y. (2021). MicroRNA-520c-3p targeting of RelA\/p65 suppresses atherosclerotic plaque formation. International Journal of Biochemistry & Cell Biology, 131, 105873.","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"5255_CR53","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3892\/mmr.2017.6717","volume":"16","author":"X Liang","year":"2017","unstructured":"Liang, X., Shangguan, W., Zhang, M., Mei, S., Wang, L., & Yang, R. (2017). miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38. Molecular Medicine Reports, 16, 1307\u20131313.","journal-title":"Molecular Medicine Reports"},{"key":"5255_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/carcin\/bgx134","volume":"39","author":"T Frixa","year":"2018","unstructured":"Frixa, T., Sacconi, A., Cioce, M., Roscilli, G., Ferrara, F. F., Aurisicchio, L., Pulito, C., Telera, S., Carosi, M., Muti, P., Strano, S., Donzelli, S., & Blandino, G. (2018). MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis, 39, 293\u2013304.","journal-title":"Carcinogenesis"},{"key":"5255_CR55","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1038\/ncomms15870","volume":"8","author":"J Cai","year":"2017","unstructured":"Cai, J., Fang, L., Huang, Y., Li, R., Xu, X., Hu, Z., Zhang, L., Yang, Y., Zhu, X., Zhang, H., Wu, J., Huang, Y., Li, J., Zeng, M., Song, E., He, Y., Zhang, L., & Li, M. (2017). Simultaneous overactivation of Wnt\/\u03b2-catenin and TGF\u03b2 signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nature Communications, 8, 15870.","journal-title":"Nature Communications"},{"key":"5255_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12575-021-00154-8","volume":"23","author":"W Feng","year":"2021","unstructured":"Feng, W., Zhang, D., & Zhang, R. (2021). Circ-ABCB10 knockdown inhibits the malignant progression of cervical cancer through microRNA-128-3p\/ZEB1 axis. Biol Proced Online, 23, 17.","journal-title":"Biol Proced Online"},{"key":"5255_CR57","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/21655979.2021.2017566","volume":"13","author":"W Fang","year":"2022","unstructured":"Fang, W., Shi, C., Wang, Y., Song, J., & Zhang, L. (2022). microRNA-128-3p inhibits CD4+ regulatory T cells enrichment by targeting interleukin 16 in gastric cancer. Bioengineered, 13, 1025\u20131038.","journal-title":"Bioengineered"},{"issue":"8","key":"5255_CR58","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3390\/cancers13081922","volume":"13","author":"J Pe\u00f1a-Asensio","year":"2021","unstructured":"Pe\u00f1a-Asensio, J., Calvo, H., Torralba, M., Miquel, J., Sanz-de-Villalobos, E., & Larrubia, J. R. (2021). Anti-PD-1\/PD-L1 based combination immunotherapy to boost antigen-specific CD8+ T cell response in hepatocellular carcinoma. Cancers (Basel)., 13(8), 1922.","journal-title":"Cancers (Basel)."},{"issue":"21","key":"5255_CR59","doi-asserted-by":"publisher","first-page":"eabd7455","DOI":"10.1126\/sciadv.abd7455","volume":"7","author":"Y Guo","year":"2021","unstructured":"Guo, Y., Lu, X., Chen, Y., Rendon, B., Mitchell, R. A., Cuatrecasas, M., Cort\u00e9s, M., Postigo, A., Liu, Y., & Dean, D. C. (2021). Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Science Advances, 7(21), eabd7455.","journal-title":"Science Advances"},{"issue":"1","key":"5255_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021). Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology & Oncology, 14(1), 10.","journal-title":"Journal of Hematology & Oncology"},{"key":"5255_CR61","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-04-278739","volume":"116","author":"W Hobo","year":"2010","unstructured":"Hobo, W., Maas, F., Adisty, N., de Witte, T., Schaap, N., van der Voort, R., & Dolstra, H. (2010). siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood, 116, 4501\u20134511.","journal-title":"Blood"},{"key":"5255_CR62","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00011-018-1192-1","volume":"67","author":"S Matsui","year":"2018","unstructured":"Matsui, S., Zhou, L., Nakayama, Y., Mezawa, M., Kato, A., Suzuki, N., Tanabe, N., Nakayama, T., Suzuki, Y., Kamio, N., Takai, H., & Ogata, Y. (2018). MiR-200b attenuates IL-6 production through IKK\u03b2 and ZEB1 in human gingival fibroblasts. Inflammation Research, 67, 965\u2013973.","journal-title":"Inflammation Research"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-025-05255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-025-05255-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-025-05255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:46:22Z","timestamp":1757173582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-025-05255-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5255"],"URL":"https:\/\/doi.org\/10.1007\/s12010-025-05255-8","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"2 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethics Committee of Peking Union Medical College Hospital (No.201302BJ24) and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards.The animal experiment research protocol was approved by the Ethics Committee of Peking Union Medical College Hospital (No.2012-BJ105) and performed in accordance with the \u201cGuidelines for the care and use of experimental animals.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Written informed consent was obtained from each subject.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Authors declared no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interests"}}]}}